Extended Use of the Wearable Cardioverter-Defibrillator: Which Patients Are Most Likely to Benefit?
Background. Wearable cardioverter-defibrillators (WCD, LifeVest, ZOLL) can protect from sudden cardiac death bridging a vulnerable period until a decision on implantable cardioverter-defibrillator (ICD) implantation can be reached. WCD is commonly used for 3 months or less. It is unknown, which pati...
Saved in:
| Main Authors: | Boldizsar Kovacs, Sven Reek, Nazmi Krasniqi, Urs Eriksson, Firat Duru |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | Cardiology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2018/7373610 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Association of BMI with adherence and outcome in heart failure patients treated with wearable cardioverter defibrillator
by: Mohammad Abumayyaleh, et al.
Published: (2025-04-01) -
Wearable cardioverter defibrillator after ICD-system explantation: data from a multicenter registry
by: Ibrahim El-Battrawy, et al.
Published: (2025-03-01) -
Benefit of implantable cardioverter defibrillator use in Japanese patients based on modified MADIT‐ICD benefit score
by: Toshinori Chiba, et al.
Published: (2025-02-01) -
Battery Longevity in Modern Implantable Cardioverter‐Defibrillators and Cardiac Resynchronization Therapy‐Defibrillators
by: Kotaro Nishino, et al.
Published: (2025-08-01) -
How to Indicate Implantable Cardioverter‐Defibrillator in Patients With Malignancy
by: Naoya Kataoka, et al.
Published: (2025-08-01)